Therapeutic drug monitoring of immunosuppressive drugs:: focus on mycophenolate mofetil and sirolimus measurement and on sampling of cyclosporine at C2

被引：0

作者：

Royer, B ^{[1
]}

Davani, S ^{[1
]}

Bérard, M ^{[1
]}

Kantelip, JP ^{[1
]}

Muret, P ^{[1
]}

机构：

[1] Hop Jean Minjoz, Lab Pharmacol Clin, F-25030 Besancon, France

来源：

ANNALES DE BIOLOGIE CLINIQUE | 2003年 / 61卷 / 03期

关键词：

immunosuppressive drug; therapeutic drug monitoring; cyclosporin; mycophenolate mofetil; sirolimus;

D O I：

暂无

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

The evolutions in treatments and clinical practices in organ transplantations led to modifications in the therapeutic drug monitoring (TDM) of immunosuppressive drugs. A focus is made regarding the C-2 sampling of cyclosporin, as well as the TDM of mycophenolate mofetil and sirolimus. A review of literature about the evolution of drug monitoring, technical methods and sampling strategies is described. Arguments in favour of TDM are thus a decrease in the frequency of both graft rejection and adverse drug reactions, however, new strategies or new targets are needed in new associations or indications.

引用

页码：251 / 258

页数：8

共 34 条

[1] Requirements for therapeutic drug monitoring of sirolimus, an immunosuppressive agent used in renal transplantation [J].

Aspeslet, LJ ;

Yatscoff, RW .

CLINICAL THERAPEUTICS, 2000, 22 :B86-B92

[2] Clinical pharmacokinetics of mycophenolate mofetil [J].

Bullingham, RES ;

Nicholls, AJ ;

Kanmm, BR .

CLINICAL PHARMACOKINETICS, 1998, 34 (06) :429-455

[3] Comparison of neoral dose monitoring with cyclosporine trough levels versus 2-hr postdose levels in stable liver transplant patients [J].

Cantarovich, M ;

Barkun, JS ;

Tchervenkov, JI ;

Besner, JG ;

Aspeslet, L ;

Metrakos, P .

TRANSPLANTATION, 1998, 66 (12) :1621-1627

[4]

Cantarovich M, 1998, CLIN TRANSPLANT, V12, P243

[5] Clinical benefit of neoral dose monitoring with cyclosporine 2-HR post-dose levels compared with trough levels in stable heart transplant patients [J].

Cantarovich, M ;

Elstein, E ;

de Varennes, B ;

Barkun, JS .

TRANSPLANTATION, 1999, 68 (12) :1839-1842

[6] C2 single-point sampling to evaluate cyclosporine exposure in long-term renal transplant recipients [J].

Citterio, F ;

Scatà, MC ;

Borzi, MT ;

Pozzetto, U ;

Castagneto, M .

TRANSPLANTATION PROCEEDINGS, 2001, 33 (7-8) :3133-3136

[7] Pharmacokinetics and metabolism of sirolimus [J].

Gallant-Haidner, HL ;

Trepanier, DJ ;

Freitag, DG ;

Yatscoff, RW .

THERAPEUTIC DRUG MONITORING, 2000, 22 (01) :31-35

[8] Higher immunosuppressive efficacy of mycophenolate mofetil in combination with FK 506 than in combination with cyclosporine A [J].

Glanemann, M ;

Klupp, J ;

Langrehr, JM ;

Schröer, G ;

Platz, KP ;

Stange, B ;

Settmacher, U ;

Bechstein, WO ;

Neuhaus, P .

TRANSPLANTATION PROCEEDINGS, 2000, 32 (03) :522-523

[9]

Holt DW, 2000, CLIN CHEM, V46, P872

[10] International federation of clinical chemistry/international association of therapeutic drug monitoring and clinical toxicology working group on immunosuppressive drug monitoring [J].

Holt, DW ;

Armstrong, VW ;

Griesmacher, A ;

Morris, RG ;

Napoli, KL ;

Shaw, LM .

THERAPEUTIC DRUG MONITORING, 2002, 24 (01) :59-67

← 1 2 3 4 →